Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo Chinese For Medical Students & Physicians A complete 20-lesson, 300-page Chinese course with a companion app in 21 languages — free forever. Download the free PDF: Amedeo Chinese PDF

Lung Cancer

Free Subscription Articles published in Cancer Sci Retrieve available abstracts of 126 articles: HTML format

Single Articles

August 2026
1. ZHAO Y, Liu Y, Xie M, Ye Z, et al
   Mitochondrial Morphology Dynamics Remodel Metabolism and Affect TKI Sensitivity in EGFR-Mutated Lung Cancer.
   Cancer Sci. 2026 Aug 13:10.1111/cas.70488. doi: 10.1111/cas.70488.
   PubMed     Abstract available
   
   
   July 2026
2. CHENG N, Jiang R, Li W, Huang W, et al
   Feiwei Heji Enhances Antitumor Immunity by MLL4-Dependent Regulation of Pyroptosis in Lung Cancer.
   Cancer Sci. 2026 Jul 31. doi: 10.1111/cas.70459.
   PubMed     Abstract available
   
   
   
3. TSURUMI K, Nomura M, Ouchi M, Yagishita S, et al
   Nicotinic Acid Restriction Enhances the Therapeutic Benefit of NAMPT Inhibition in Small-Cell Lung Cancer Models.
   Cancer Sci. 2026 Jul 28:10.1111/cas.70486. doi: 10.1111/cas.70486.
   PubMed     Abstract available
   
   
   
4. WEI C, Liu X, Hu S, Shen X, et al
   MEN1 Deficiency Drives Lung Cancer Progression via Activation of MMP10-Mediated Angiogenesis.
   Cancer Sci. 2026 Jul 21:10.1111/cas.70470. doi: 10.1111/cas.70470.
   PubMed     Abstract available
   
   
   June 2026
5. TERAMOTO K, Kaku R, Igarashi T, Hashimoto M, et al
   Prospective Trial on Tolerability and Efficacy of Adjuvant Nedaplatin Plus Docetaxel for Non-Small Cell Lung Cancer.
   Cancer Sci. 2026 Jun 12. doi: 10.1111/cas.70446.
   PubMed     Abstract available
   
   
   
6. SHAO M, Yao J, Zhao L, Zhu L, et al
   Final Analysis of Neoadjuvant Sintilimab Plus Chemotherapy in IB-IIIA Non-Small-Cell Lung Cancer: Phase 2 neoSCORE Trial.
   Cancer Sci. 2026 Jun 7. doi: 10.1111/cas.70442.
   PubMed     Abstract available
   
   
   
7. TANAKA T, Fujitani M, Taoka M, Shimomura I, et al
   Afatinib Overcomes Osimertinib Resistance via Egfr V804F Mutation in a Syngeneic Egfr-Mutant Lung Cancer Mouse Model.
   Cancer Sci. 2026 Jun 1. doi: 10.1111/cas.70431.
   PubMed     Abstract available
   
   
   
8. KUMEDA H, Hirabayashi K, Mishima S, Morita K, et al
   Bispecific Ligand-Based EphB4 CAR-T Cells Generated Using Ephrin-B2 Show Potent Antitumor Activity Against Lung Adenocarcinoma.
   Cancer Sci. 2026;117:1724-1735.
   PubMed     Abstract available
   
   
   May 2026
9. NAGANO Y, Yokouchi H, Saito R, Honjo O, et al
   Afatinib Versus Osimertinib for Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: Real-World Outcomes.
   Cancer Sci. 2026 May 31. doi: 10.1111/cas.70400.
   PubMed     Abstract available
   
   
   
10. KINOSHITA T, Ohta S, Wakui S, Maeda C, et al
    Tumor-Derived Extracellular Vesicles in Plasma for Predicting Anti-PD-1 Antibody Efficacy in Non-Small Cell Lung Cancer.
    Cancer Sci. 2026 May 24. doi: 10.1111/cas.70412.
    PubMed     Abstract available
    
    
    
11. SHIMIZU J, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy in Older Patients With Lung Cancer in Japan.
    Cancer Sci. 2026 May 14. doi: 10.1111/cas.70411.
    PubMed     Abstract available
    
    
    
12. JIN Y, Zhang T, Wu Z, Liang Y, et al
    SMURF1 Regulates CTCF-HOXA10 Axis and Promotes Tumor Progression in Nasopharyngeal Carcinoma.
    Cancer Sci. 2026;117:1346-1361.
    PubMed     Abstract available
    
    
    
13. LIANG Y, Ma H, Sun W, Chen Y, et al
    The Overlooked Autoantibody Repertoire: Exploring the Biomarker Potential of Downregulated Autoantibodies in NSCLC.
    Cancer Sci. 2026;117:1244-1259.
    PubMed     Abstract available
    
    
    April 2026
14. GOTO Y, Nishio M, Ohashi K, Osoegawa A, et al
    Plasma Protein Analysis for Biomarker Discovery in Lung Cancer Treated With Atezolizumab Combination Therapy in J-TAIL-2.
    Cancer Sci. 2026 Apr 21. doi: 10.1111/cas.70375.
    PubMed     Abstract available
    
    
    
15. MOURI A, Kagamu H, Tamada K, Nishio M, et al
    Analysis of Peripheral T Cell Profiling and Plasma Proteomics in Advanced NSCLC Patients Treated With Atezolizumab.
    Cancer Sci. 2026;117:904-916.
    PubMed     Abstract available
    
    
    
16. MATSUMOTO K, Naito Y, Shiroyama T, Tamiya M, et al
    Impact of Sequential Ramucirumab Plus Docetaxel After PD-1 Inhibitors on Anti-PD-1 Antibody-Bound T-Cell Dynamics and Clinical Outcomes.
    Cancer Sci. 2026;117:929-942.
    PubMed     Abstract available
    
    
    
17. LEE JS, Sugawara S, Kang JH, Kim HR, et al
    Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.
    Cancer Sci. 2026;117:1124-1135.
    PubMed     Abstract available
    
    
    
18. YOSHIDA A, Abe S, Izumi T, Itakura S, et al
    Cancer-Specific Antihuman Podoplanin Antibody chLpMab-2f Exerts Antitumor Effects Against Pleural Mesothelioma.
    Cancer Sci. 2026;117:917-928.
    PubMed     Abstract available
    
    
    
19. MURASE Y, Nanjo S, Arai S, Kondo S, et al
    Therapeutic Strategies to Overcome Payload Resistance of Trastuzumab Deruxtecan in HER2-Positive Cancers.
    Cancer Sci. 2026;117:996-1009.
    PubMed     Abstract available
    
    
    March 2026
20. KESHARWANI P, Nasir N, Wahab S, Gupta G, et al
    PEGylated Chitosan Nanoparticles: Engineering Multifunctional Platforms for Targeted Cervical and Lung Cancer Treatment.
    Cancer Sci. 2026 Mar 31. doi: 10.1111/cas.70361.
    PubMed     Abstract available
    
    
    
21. TSURUDA T, Kodama M, Nakayama KI
    Small Cell Lung Cancer Establishes a Metabolic Autocrine Mechanism Through Active Extracellular ATP Transport.
    Cancer Sci. 2026 Mar 2. doi: 10.1111/cas.70350.
    PubMed     Abstract available
    
    
    
22. ONO Y, Otsu H, Masuda T, Kosai K, et al
    PSMD12 Overexpression Promotes Lung Adenocarcinoma Progression via Ubiquitin-Proteasome Pathway Dysregulation.
    Cancer Sci. 2026;117:644-656.
    PubMed     Abstract available
    
    
    February 2026
23. KURIBAYASHI T, Nishimura J, Okawa S, Taoka M, et al
    TGF-beta Inhibitor Potentiates Osimertinib-Induced Anti-Tumor Immunity in Egfr-Mutant Lung Cancer.
    Cancer Sci. 2026 Feb 27. doi: 10.1111/cas.70352.
    PubMed     Abstract available
    
    
    
24. KONO K, Tanino R, Tsubata Y, Haque EF, et al
    Microtubule Inhibitors Induce Cross-Resistance to Osimertinib Through CaMKII Activation in EGFR-Mutated NSCLC.
    Cancer Sci. 2026;117:418-428.
    PubMed     Abstract available
    
    
    
25. LUO X, Xu J, Wang Z, Wang X, et al
    Spatial Location of SPP1(+)TAMs and Mutually Exclusive Subsets Based on Single-Cell and Transcriptome Data.
    Cancer Sci. 2026;117:548-565.
    PubMed     Abstract available
    
    
    January 2026
26. NAM SY, Jo J, Choi SH
    Effect Modification by Cofactors in the Impact of Body Mass Index Change on the Risk of Lung Cancer.
    Cancer Sci. 2026 Jan 23. doi: 10.1111/cas.70332.
    PubMed     Abstract available
    
    
    
27. SATO S, Yilmaz N, Arai S, Sakai K, et al
    MET Enhances Amivantamab Binding to EGFR and Antibody-Dependent Cellular Toxicity.
    Cancer Sci. 2026;117:118-129.
    PubMed     Abstract available
    
    
    December 2025
28. SALEH MF, Nita A, Ohta Y, Kobayashi A, et al
    Hippo Pathway Drives Durable Non-Cell-Autonomous Ferroptosis Resistance in Lung Cancer.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70299.
    PubMed     Abstract available
    
    
    
29. TANAKA F, Watanabe Y, Sugawara S, Okami J, et al
    Perioperative Nivolumab in Resectable Non-Small Cell Lung Cancer: A Subanalysis of Japanese Patients From Checkmate 77T.
    Cancer Sci. 2025 Dec 23. doi: 10.1111/cas.70300.
    PubMed     Abstract available
    
    
    
30. OKADA M, Sugawara S, Watanabe Y, Saito H, et al
    IMpower010: 5-Year Outcomes of Atezolizumab in Japanese Patients With Resected Stage IB-IIIA Non-Small Cell Lung Cancer.
    Cancer Sci. 2025 Dec 19. doi: 10.1111/cas.70297.
    PubMed     Abstract available
    
    
    
31. YOSHIOKA H, Nishio M, Ohashi K, Osoegawa A, et al
    Atezolizumab + Chemotherapy for Advanced Non-Small Cell Lung Cancer in Japanese Clinical Practice (J-TAIL-2).
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70242.
    PubMed     Abstract available
    
    
    
32. TAKAYAMA-ISAGAWA Y, Komura D, Isagawa T, Amano Y, et al
    A Transcriptomic Analysis of Cancer-Stromal Interactome in Lung Cancer Xenograft Models.
    Cancer Sci. 2025 Dec 11. doi: 10.1111/cas.70270.
    PubMed     Abstract available
    
    
    
33. LI J, Zhao F, Wang Z, Yang S, et al
    KAT2A Deficiency Suppresses Lung Cancer Progression by Downregulating MYC Through Decreasing MYC Succinylation.
    Cancer Sci. 2025 Dec 9. doi: 10.1111/cas.70286.
    PubMed     Abstract available
    
    
    
34. TOZUKA T, Noro R, Naito Y, Miura N, et al
    ACTN4 Gene Amplification and Actinin-4 Protein Expression for Osimertinib Efficacy in EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:3367-3375.
    PubMed     Abstract available
    
    
    
35. LIU SY, Lin LT, Chang CH, Chen YJ, et al
    Liposomal (188)Rhenium Plus Macrophage Depletion Enhances Anti-PD-L1 Efficacy and B Cell Infiltration Against Lung Metastatic Cancer.
    Cancer Sci. 2025;116:3442-3458.
    PubMed     Abstract available
    
    
    November 2025
36. JIANG Y, Liang Q, Zhu Y, Liang X, et al
    Third-Generation EGFR-TKIs Combined With Chemotherapy in Advanced Non-Small Cell Lung Cancer: A Real-World Study.
    Cancer Sci. 2025 Nov 28. doi: 10.1111/cas.70269.
    PubMed     Abstract available
    
    
    
37. 
    Correction to "Trametinib Overcomes KRAS-G12V-Induced Osimertinib Resistance in a Leptomeningeal Carcinomatosis Model of EGFR-Mutant Lung Cancer".
    Cancer Sci. 2025 Nov 24. doi: 10.1111/cas.70278.
    PubMed    
    
    
    
38. WEI T, Cao W, Zhang Q, Wu E, et al
    Pulmonary Delivery of TCR Bispecific Proteins via Mesenchymal Stem Cells Facilitates Efficient Clearance of Lung Cancers.
    Cancer Sci. 2025;116:3185-3195.
    PubMed     Abstract available
    
    
    
39. KIWAKI T, Tanaka H, Kawaguchi M, Umekita Y, et al
    Low-Density Lipoprotein Receptor-Related Protein 11 Promotes Proliferation in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:3090-3101.
    PubMed     Abstract available
    
    
    
40. KITAZONO S, Ono A, Kawamura T, Hataji O, et al
    Amivantamab Plus Chemotherapy in Japanese Patients With EGFR Exon 20 Insertions NSCLC.
    Cancer Sci. 2025;116:3139-3148.
    PubMed     Abstract available
    
    
    
41. CHEN J, Pan Y, Zhang B, Li M, et al
    Comparison of the Efficacy of Different First-Line Therapies for EGFR L858R-Mutated NSCLC Patients With Brain Metastases.
    Cancer Sci. 2025;116:3125-3138.
    PubMed     Abstract available
    
    
    October 2025
42. TAKAOKA H, Terai H, Nakamura K, Mizuno T, et al
    Clinical Application of In-House Comprehensive Genomic Profiling for Thoracic Cancer: Insights From a Japanese Hospital.
    Cancer Sci. 2025;116:2819-2830.
    PubMed     Abstract available
    
    
    
43. TERASHIMA Y, Park S, Ikeuchi H, Hayashi T, et al
    Discovery of Novel RASGRF2 Fusions as a Therapeutic Target in Lung Adenocarcinoma of Never or Light Smokers.
    Cancer Sci. 2025;116:2868-2881.
    PubMed     Abstract available
    
    
    
44. NGUYEN TTN, Chen PY, Zheng MY, Lin TK, et al
    Intrinsic PDL1 Signaling Modulates TGFBI-Mediated Growth Suppression in Lung Adenocarcinoma.
    Cancer Sci. 2025;116:2737-2749.
    PubMed     Abstract available
    
    
    
45. ZHANG Z, Wang C, Guo Y, Zhao Z, et al
    HROB Induces Lung Adenocarcinoma Progression via ZC3HC1-CCNB1 Axis Regulation and Cell Cycle Dysregulation.
    Cancer Sci. 2025;116:2699-2711.
    PubMed     Abstract available
    
    
    September 2025
46. ZENKE Y, Shiraishi Y, Goto Y, Azuma K, et al
    Durvalumab Post Concurrent Chemoradiotherapy in Japanese Patients With Limited-Stage Small-Cell Lung Cancer in the Phase 3 ADRIATIC Trial.
    Cancer Sci. 2025 Sep 21. doi: 10.1111/cas.70188.
    PubMed     Abstract available
    
    
    
47. YANG W, Wu X, Cai F, Guo Z, et al
    NFATc4 Promotes Lung Adenocarcinoma Progression via the CCNB1/CDK1 Pathway and Is a Potential Prognostic Biomarker.
    Cancer Sci. 2025;116:2400-2412.
    PubMed     Abstract available
    
    
    
48. HORI K, Tanaka I, Sato T, Sato M, et al
    PBK Expression Promotes the Aggressive Phenotypes of Mesothelioma.
    Cancer Sci. 2025;116:2413-2426.
    PubMed     Abstract available
    
    
    August 2025
49. MO X, He J, Shen X, Li C, et al
    Connexin43 Promotes the Invasion and Metastasis of Lung Squamous Cell Carcinoma via GJIC-Dependent Ca(2+)/ERK Signaling Activation.
    Cancer Sci. 2025;116:2086-2100.
    PubMed     Abstract available
    
    
    
50. YOKOYAMA T, Saitoh M, Miyazawa K
    TGF-beta Enhances Doxorubicin Resistance and Anchorage-Independent Growth in Cancer Cells by Inducing ALDH1A1 Expression.
    Cancer Sci. 2025;116:2176-2188.
    PubMed     Abstract available
    
    
    
51. KIJIMA T, Kato T, Goto Y, Kuribayashi K, et al
    KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural Mesothelioma.
    Cancer Sci. 2025;116:2208-2217.
    PubMed     Abstract available
    
    
    
52. WEI T, Cheng Y, Ge J, Zhu M, et al
    The Pro-Apoptotic Effect of Glucose Restriction in NSCLC via AMPK-Regulated Circadian Clock Gene Bmal1.
    Cancer Sci. 2025;116:2101-2112.
    PubMed     Abstract available
    
    
    July 2025
53. HOSOYA K, Ozasa H, Yoshida H, Ajimizu H, et al
    Novel TEAD1 Inhibitor VT103 Enhances Dabrafenib Efficacy in BRAF V600E Mutated Lung Adenocarcinoma via Survivin Downregulation.
    Cancer Sci. 2025;116:1883-1896.
    PubMed     Abstract available
    
    
    June 2025
54. MEN B, Chen Z, Ge H, Yang Z, et al
    Dauricine Overcomes Osimertinib Resistance in Lung Cancer by Inducing Ferroptosis via Stabilizing SAT1.
    Cancer Sci. 2025 Jun 8. doi: 10.1111/cas.70113.
    PubMed     Abstract available
    
    
    
55. HONGU T, Sarenqiqige, Shandan, Kusunoki H, et al
    Permeable Lung Vasculature Creates Chemoresistant Endothelial Niche by Producing SERPINE1 at Breast Cancer Metastatic Sites.
    Cancer Sci. 2025;116:1604-1615.
    PubMed     Abstract available
    
    
    
56. ZHANG Y, Xu Y, Jin H, Liu T, et al
    Spatial Heterogeneity of PD-L1 Expression as a Biomarker for Third-Generation EGFR-TKI Response in Advanced EGFR-Mutant NSCLC.
    Cancer Sci. 2025;116:1648-1660.
    PubMed     Abstract available
    
    
    
57. HUANG J, Yuan Y, Guo L, Xia G, et al
    The impact of BTK knockdown on lung adenocarcinoma growth and immune response.
    Cancer Sci. 2025;116:1550-1564.
    PubMed     Abstract available
    
    
    May 2025
58. MIYASHITA Y, Tajima K, Izumi K, Matsumoto N, et al
    Novel Approach to Overcome Osimertinib Resistance Using Bromodomain and Extra-Terminal Domain Inhibitors.
    Cancer Sci. 2025;116:1392-1404.
    PubMed     Abstract available
    
    
    
59. MONIWA K, Tokita S, Sumi T, Saijo H, et al
    Loss of Tapasin in Tumors Potentiates T-Cell Recognition and Anti-Tumor Effects of Immune Checkpoint Blockade.
    Cancer Sci. 2025;116:1203-1213.
    PubMed     Abstract available
    
    
    April 2025
60. OCHI T, Fujiki R, Fukuyo M, Rahmutulla B, et al
    Association of Intratumoral Bacterial Abundance With Lung Cancer Prognosis in Chiba University Hospital Cohort.
    Cancer Sci. 2025 Apr 11. doi: 10.1111/cas.70080.
    PubMed     Abstract available
    
    
    
61. UTSUMI T, Mizuta H, Seto Y, Uchibori K, et al
    AXL-Mediated Drug Resistance in ALK-Rearranged NSCLC Enhanced by GAS6 From Macrophages and MMP11 Positive Fibroblasts.
    Cancer Sci. 2025;116:1034-1047.
    PubMed     Abstract available
    
    
    
62. LI H, Tang C, Zhao P, Zhong R, et al
    Multiple Kinase Small Molecule Inhibitor Tinengotinib (TT-00420) Alone or With Chemotherapy Inhibit the Growth of SCLC.
    Cancer Sci. 2025;116:951-965.
    PubMed     Abstract available
    
    
    
63. DING J, Wang X, Yang H, Zhang L, et al
    IGF2BP3 Triggers STAT3 Pathway by Stabilizing SRC RNA in an m6A-Dependent Manner to Promote Lymphatic Metastasis in LUAD.
    Cancer Sci. 2025;116:936-950.
    PubMed     Abstract available
    
    
    
64. LIU X, Yu D, Yu Z, Su S, et al
    LHPP-P38 MAPK/ERK-ETS1 Axis Negative Feedback Signaling Restrains Progression in Breast Cancer.
    Cancer Sci. 2025;116:923-935.
    PubMed     Abstract available
    
    
    
65. WANG P, Xu J, You W, Li J, et al
    CYP24A1 Binding to FUS Maintains Tumor Properties by Regulating the miR-200c/ZEB1/EMT Axis.
    Cancer Sci. 2025;116:910-922.
    PubMed     Abstract available
    
    
    March 2025
66. 
    Correction to "Celastrol Induces Proteasomal Degradation of FANCD2 to Sensitize Lung Cancer Cells to DNA Crosslinking Agents".
    Cancer Sci. 2025 Mar 29. doi: 10.1111/cas.70066.
    PubMed    
    
    
    
67. SHEN S, Wu Y, Shao Z, Li Y, et al
    LTF as a Potential Predictive Biomarker for Durable Benefit From First-Line Chemo-Immunotherapy in Small Cell Lung Cancer.
    Cancer Sci. 2025 Mar 17. doi: 10.1111/cas.70049.
    PubMed     Abstract available
    
    
    
68. SAKAMOTO S, Inoue H, Takino T, Kohda Y, et al
    Claudin-11 Enhances Invasive and Metastatic Abilities of Small-Cell Lung Cancer Through MT1-MMP Activation.
    Cancer Sci. 2025 Mar 13. doi: 10.1111/cas.70038.
    PubMed     Abstract available
    
    
    
69. ZHANG Y, Xu Y, Xu J, Zhong H, et al
    Osimertinib for EGFR-Mutant NSCLC Patients With Acquired T790M and EGFR Amplification After First-Generation EGFR-TKI Resistance.
    Cancer Sci. 2025;116:753-763.
    PubMed     Abstract available
    
    
    
70. ZHU P, Li Z, Sun Y, Liu T, et al
    Persist or resist: Immune checkpoint inhibitors in EGFR-mutated NSCLC.
    Cancer Sci. 2025;116:581-591.
    PubMed     Abstract available
    
    
    
71. CHEN Y, Pan G, Yang Y, Wu H, et al
    Tumor exosomal RNPEP promotes lung metastasis of liver cancer via inducing cancer-associated fibroblast activation.
    Cancer Sci. 2025;116:792-807.
    PubMed     Abstract available
    
    
    February 2025
72. PAN Z, Qian Y, Wang Y, Zhang T, et al
    STAT3 Inhibition Prevents Adaptive Resistance and Augments NK Cell Cytotoxicity to KRAS(G12C) Inhibitors in Nonsmall Cell Lung Cancer.
    Cancer Sci. 2025 Feb 12. doi: 10.1111/cas.70017.
    PubMed     Abstract available
    
    
    
73. OI H, Taki T, Kuroe T, Sakamoto N, et al
    NETosis in pulmonary pleomorphic carcinoma.
    Cancer Sci. 2025;116:524-532.
    PubMed     Abstract available
    
    
    January 2025
74. WU Y, Cui Y, Zheng X, Yao X, et al
    Integrated machine learning to predict the prognosis of lung adenocarcinoma patients based on SARS-COV-2 and lung adenocarcinoma crosstalk genes.
    Cancer Sci. 2025;116:95-111.
    PubMed     Abstract available
    
    
    December 2024
75. ZHAO Z, Bhardwaj M, Fan Z, Li X, et al
    Smoking-independent DNA methylation markers for lung cancer risk: External validation in a large population-based cohort study.
    Cancer Sci. 2024 Dec 3. doi: 10.1111/cas.16414.
    PubMed     Abstract available
    
    
    
76. IWASAKI T, Shirota H, Sasaki K, Ouchi K, et al
    Specific cancer types and prognosis in patients with variations in the KEAP1-NRF2 system: A retrospective cohort study.
    Cancer Sci. 2024;115:4034-4044.
    PubMed     Abstract available
    
    
    November 2024
77. KA M, Matsumoto Y, Ando T, Hinata M, et al
    Integrin-alpha5 expression and its role in non-small cell lung cancer progression.
    Cancer Sci. 2024 Nov 24. doi: 10.1111/cas.16416.
    PubMed     Abstract available
    
    
    
78. SAKAI K, Ohara S, Tanaka J, Suda K, et al
    Improved platelet separation performance from whole blood using an acoustic fluidics system.
    Cancer Sci. 2024;115:3795-3803.
    PubMed     Abstract available
    
    
    
79. TAKI T, Koike Y, Adachi M, Sakashita S, et al
    A novel histopathological feature of spatial tumor-stroma distribution predicts lung squamous cell carcinoma prognosis.
    Cancer Sci. 2024;115:3804-3816.
    PubMed     Abstract available
    
    
    October 2024
80. XU F, Wang C, Li H, Yu B, et al
    Evaluation of cfDNA fragmentation characteristics in plasma for the diagnosis of lung cancer: A prospective cohort study.
    Cancer Sci. 2024 Oct 28. doi: 10.1111/cas.16360.
    PubMed     Abstract available
    
    
    September 2024
81. FURUTA M, Horinouchi H, Yokota I, Yamaguchi T, et al
    Durvalumab after chemoradiotherapy for locoregional recurrence of completely resected non-small-cell lung cancer (NEJ056).
    Cancer Sci. 2024 Sep 15. doi: 10.1111/cas.16340.
    PubMed     Abstract available
    
    
    
82. NISHITSUJI K, Mito R, Ikezaki M, Yano H, et al
    Impacts of cytoplasmic p53 aggregates on the prognosis and the transcriptome in lung squamous cell carcinoma.
    Cancer Sci. 2024;115:2947-2960.
    PubMed     Abstract available
    
    
    August 2024
83. WU ZY, Yang DW, He YQ, Wang TM, et al
    Plasma ofCS-modified CD44 predicts the survival of patients with lung cancer.
    Cancer Sci. 2024 Aug 27. doi: 10.1111/cas.16319.
    PubMed     Abstract available
    
    
    
84. ONDA N, Nakamichi S, Hirao M, Matsuda K, et al
    Afatinib plus PEM and CBDCA overcome osimertinib resistance in EGFR-mutated NSCLC with high thrombospondin-1 expression.
    Cancer Sci. 2024;115:2718-2728.
    PubMed     Abstract available
    
    
    
85. FUJIKAWA Y, Kawabata S, Tsujino K, Yamada H, et al
    Boron neutron capture therapy delays the decline in neurological function in a mouse model of metastatic spinal tumors.
    Cancer Sci. 2024;115:2774-2785.
    PubMed     Abstract available
    
    
    
86. SHI Y, Zhang J, Li J, He J, et al
    USP15, activated by TFAP4 transcriptionally, stabilizes SHC1 via deubiquitination and deteriorates renal cell carcinoma.
    Cancer Sci. 2024;115:2617-2629.
    PubMed     Abstract available
    
    
    
87. LI C, Hu M, Cai S, Yang G, et al
    Dysfunction of CD8(+) T cells around tumor cells leads to occult lymph node metastasis in NSCLC patients.
    Cancer Sci. 2024;115:2528-2539.
    PubMed     Abstract available
    
    
    July 2024
88. AHAMED MT, Forshed J, Levitsky A, Lehtio J, et al
    Multiplex plasma protein assays as a diagnostic tool for lung cancer.
    Cancer Sci. 2024 Jul 30. doi: 10.1111/cas.16300.
    PubMed     Abstract available
    
    
    
89. MATSUI Y, Yamada T, Katayama Y, Hirai S, et al
    Initial AXL and MCL-1 inhibition contributes to abolishing lazertinib tolerance in EGFR-mutant lung cancer cells.
    Cancer Sci. 2024 Jul 22. doi: 10.1111/cas.16292.
    PubMed     Abstract available
    
    
    
90. WANG Y, Ma L, Chen Y, Yun W, et al
    Prognostic effect of TCF1+ CD8+ T cell and TOX+ CD8+ T cell infiltration in lung adenocarcinoma.
    Cancer Sci. 2024;115:2184-2195.
    PubMed     Abstract available
    
    
    June 2024
91. SHAO Y, Zhang J, Feng Z, Wu W, et al
    Outcomes in non-small cell lung cancer with uncommon epidermal growth factor receptor L858 substitutions under first-line epidermal growth factor receptor tyrosine kinase inhibitors: A large real-world cohort study.
    Cancer Sci. 2024 Jun 26. doi: 10.1111/cas.16250.
    PubMed     Abstract available
    
    
    
92. ZHANG C, Yang L, Zhao W, Zhu H, et al
    A heterogeneous tumor immune microenvironment of uncommon epidermal growth factor receptor mutant non-small cell lung cancer.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16253.
    PubMed     Abstract available
    
    
    
93. WANG J, Wang S, Yang H, Wang R, et al
    Methyltransferase like-14 suppresses growth and metastasis of non-small-cell lung cancer by decreasing LINC02747.
    Cancer Sci. 2024 Jun 18. doi: 10.1111/cas.16254.
    PubMed     Abstract available
    
    
    
94. GUO Y, Kasai Y, Tanaka Y, Ohashi-Kumagai Y, et al
    IGSF3 is a homophilic cell adhesion molecule that drives lung metastasis of melanoma by promoting adhesion to vascular endothelium.
    Cancer Sci. 2024;115:1936-1947.
    PubMed     Abstract available
    
    
    
95. FUKUDA H, Arai K, Mizuno H, Nishito Y, et al
    Molecular subtypes of lung adenocarcinoma present distinct immune tumor microenvironments.
    Cancer Sci. 2024;115:1763-1777.
    PubMed     Abstract available
    
    
    
96. RAUT JR, Bhardwaj M, Schottker B, Holleczek B, et al
    Cancer-specific risk prediction with a serum microRNA signature.
    Cancer Sci. 2024;115:2049-2058.
    PubMed     Abstract available
    
    
    May 2024
97. SHIBA-ISHII A, Takemura N, Kawai H, Matsubara D, et al
    Histologic transformation of non-small-cell lung cancer in response to tyrosine kinase inhibitors: Current knowledge of genetic changes and molecular mechanisms.
    Cancer Sci. 2024 May 27. doi: 10.1111/cas.16192.
    PubMed     Abstract available
    
    
    
98. DUCH P, Diaz-Valdivia N, Gabasa M, Ikemori R, et al
    Aberrant TIMP-1 production in tumor-associated fibroblasts drives the selective benefits of nintedanib in lung adenocarcinoma.
    Cancer Sci. 2024;115:1505-1519.
    PubMed     Abstract available
    
    
    April 2024
99. ZHANG C, Sun N, Fei Q, Peng L, et al
    MEN1 deficiency stabilizes PD-L1 and promotes tumor immune evasion of lung cancer.
    Cancer Sci. 2024 Apr 30. doi: 10.1111/cas.16196.
    PubMed     Abstract available
    
    
    
100. OTANI Y, Katayama H, Zhu Y, Huang R, et al
     Adrenergic microenvironment driven by cancer-associated Schwann cells contributes to chemoresistance in patients with lung cancer.
     Cancer Sci. 2024 Apr 27. doi: 10.1111/cas.16164.
     PubMed     Abstract available
     
     
     
101. ALANAZI M, Weng T, McLeod L, Gearing LJ, et al
     Cytosolic DNA sensor AIM2 promotes KRAS-driven lung cancer independent of inflammasomes.
     Cancer Sci. 2024 Apr 9. doi: 10.1111/cas.16171.
     PubMed     Abstract available
     
     
     
102. MORISE M, Kato T, Matsumoto S, Inoue T, et al
     Long-term experience with tepotinib in Japanese patients with MET exon 14 skipping NSCLC from the Phase II VISION study.
     Cancer Sci. 2024;115:1296-1305.
     PubMed     Abstract available
     
     
     
103. MIZOTE Y, Inoue T, Akazawa T, Kunimasa K, et al
     Potent CTLs can be induced against tumor cells in an environment of lower levels of systemic MFG-E8.
     Cancer Sci. 2024;115:1114-1128.
     PubMed     Abstract available
     
     
     March 2024
104. 
     Correction to: Phytochemical library screening reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
     Cancer Sci. 2024 Mar 20. doi: 10.1111/cas.16163.
     PubMed    
     
     
     
105. ISHIDA M, Iwasaku M, Doi T, Ishikawa T, et al
     Nationwide data from comprehensive genomic profiling assays for detecting driver oncogenes in non-small cell lung cancer.
     Cancer Sci. 2024 Mar 7. doi: 10.1111/cas.16130.
     PubMed     Abstract available
     
     
     
106. WANG S, Wang J, Gong W, Zhang F, et al
     ILT4 facilitates angiogenesis in non-small cell lung cancer.
     Cancer Sci. 2024 Mar 3. doi: 10.1111/cas.16126.
     PubMed     Abstract available
     
     
     February 2024
107. KAJIWARA N, Kakihana M, Maeda J, Kaneko M, et al
     Salivary metabolomic biomarkers for non-invasive lung cancer detection.
     Cancer Sci. 2024 Feb 28. doi: 10.1111/cas.16112.
     PubMed     Abstract available
     
     
     
108. KAWAI S, Lin Y, Tsuge H, Ito H, et al
     Body mass index and lung cancer risk: Pooled analysis of 10 prospective cohort studies in Japan.
     Cancer Sci. 2024 Feb 4. doi: 10.1111/cas.16093.
     PubMed     Abstract available
     
     
     
109. YONEDA H, Mitsuhashi A, Yoshida A, Ogino H, et al
     Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.
     Cancer Sci. 2024;115:357-368.
     PubMed     Abstract available
     
     
     
110. HASEGAWA S, Shintani Y, Takuwa T, Aoe K, et al
     Nationwide prospective registry database of patients with newly diagnosed untreated pleural mesothelioma in Japan.
     Cancer Sci. 2024;115:507-528.
     PubMed     Abstract available
     
     
     January 2024
111. TSUJI K, Mizugaki H, Yokoo K, Kobayashi M, et al
     Durvalumab after chemoradiotherapy in non-small cell lung cancer with EGFR mutation: A real-world study (HOT2101).
     Cancer Sci. 2024 Jan 29. doi: 10.1111/cas.16094.
     PubMed     Abstract available
     
     
     
112. ZHANG J, Li Y, Yang Y, Huang J, et al
     A novel iTreg-related signature for prognostic prediction in lung adenocarcinoma.
     Cancer Sci. 2024;115:109-124.
     PubMed     Abstract available
     
     
     December 2023
113. SHIMOMURA Y, Sawa K, Imai T, Ihara Y, et al
     Treatment sequencing after failure to alectinib in patients with anaplastic lymphoma kinase-positive non-small-cell lung cancer.
     Cancer Sci. 2023 Dec 27. doi: 10.1111/cas.16056.
     PubMed     Abstract available
     
     
     
114. HUANG R, Wu D, Zhang K, Hu G, et al
     ARID1A loss induces P4HB to activate fibroblasts to support lung cancer cell growth, invasion, and chemoresistance.
     Cancer Sci. 2023 Dec 15. doi: 10.1111/cas.16052.
     PubMed     Abstract available
     
     
     
115. MITSUDOMI T, Ito H, Okada M, Sugawara S, et al
     Neoadjuvant nivolumab plus chemotherapy in resectable non-small-cell lung cancer in Japanese patients from CheckMate 816.
     Cancer Sci. 2023 Dec 14. doi: 10.1111/cas.16030.
     PubMed     Abstract available
     
     
     
116. 
     Correction to Brigatinib in Japanese patients with ALK-positive non-small-cell lung cancer: Final results of the phase 2 J-ALTA trial.
     Cancer Sci. 2023 Dec 10. doi: 10.1111/cas.16000.
     PubMed    
     
     
     
117. SUMITOMO R, Menju T, Shimazu Y, Toyazaki T, et al
     M2-like tumor-associated macrophages promote epithelial-mesenchymal transition through the transforming growth factor beta/Smad/zinc finger e-box binding homeobox pathway with increased metastatic potential and tumor cell proliferation in lung squamou
     Cancer Sci. 2023;114:4521-4534.
     PubMed     Abstract available
     
     
     
118. WANG Q, Song X, Zhao F, Chen Q, et al
     Noninvasive diagnosis of pulmonary nodules using a circulating tsRNA-based nomogram.
     Cancer Sci. 2023;114:4607-4621.
     PubMed     Abstract available
     
     
     November 2023
119. FUJIMOTO K, Matsumoto Y, Imabayashi T, Uchimura K, et al
     Suitability of respiratory endoscopy for sampling malignant thoracic tumors for comprehensive genomic profiling.
     Cancer Sci. 2023;114:4401-4412.
     PubMed     Abstract available
     
     
     
120. KANG N, Fan B, Sun Y, Xue P, et al
     Novel specific anti-ESM1 antibodies overcome tumor bevacizumab resistance by suppressing angiogenesis and metastasis.
     Cancer Sci. 2023;114:4413-4425.
     PubMed     Abstract available
     
     
     October 2023
121. NAKANISHI T, Yoneshima Y, Okamura K, Yanagihara T, et al
     MicroRNA-326 negatively regulates CD155 expression in lung adenocarcinoma.
     Cancer Sci. 2023;114:4101-4113.
     PubMed     Abstract available
     
     
     
122. KUDO H, Morishima T, Fujii M, Nagayasu M, et al
     Prognostic impact of the presence or absence of prior cancer in patients with cancer using cure models: A population-based study.
     Cancer Sci. 2023;114:4041-4051.
     PubMed     Abstract available
     
     
     September 2023
123. HUAI Q, Luo C, Song P, Bie F, et al
     Peripheral blood inflammatory biomarkers dynamics reflect treatment response and predict prognosis in non-small cell lung cancer patients with neoadjuvant immunotherapy.
     Cancer Sci. 2023 Sep 20. doi: 10.1111/cas.15964.
     PubMed     Abstract available
     
     
     
124. ANDO C, Ichihara E, Nishi T, Morita A, et al
     Efficacy of gilteritinib in comparison with alectinib for the treatment of ALK-rearranged non-small cell lung cancer.
     Cancer Sci. 2023 Sep 15. doi: 10.1111/cas.15958.
     PubMed     Abstract available
     
     
     
125. HINOKUMA H, Kanamori Y, Ikeda K, Hao L, et al
     Distinct functions between ferrous and ferric iron in lung cancer cell growth.
     Cancer Sci. 2023 Sep 8. doi: 10.1111/cas.15949.
     PubMed     Abstract available
     
     
     
126. CHEN Y, Jin L, Ma Y, Liu Y, et al
     BACH1 promotes lung adenocarcinoma cell metastasis through transcriptional activation of ITGA2.
     Cancer Sci. 2023;114:3568-3582.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum